FOXO3 and chronic myelogenous leukemia, BCR-ABL1 positive: A combination strategy consisting of both TGFβ and Bcr-Abl kinase inhibition and FOXO3a deficiency resulted in efficient depletion of LSCs and suppressed CML development [93].